In a welcome move, Semler Scientific saw its Relative Strength Rating improve from 68 to 74 on Tuesday.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the best stocks tend to have an RS Rating of over 80 as they launch their largest price moves. See if Semler Scientific can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Semler Scientific has climbed more than 5% past a 29.93 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Taking a look at revenue and profit performance, the company has posted two quarters of accelerating earnings growth. Revenue growth has been less impressive, coming in at -18% in the most recent quarterly report.
Semler Scientific earns the No. 29 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
